Laboratory Medicine Program

Prostate Carcinoma

Clinical Decription:
Prostate cancer ranges from indolent malignancies, which may not need treatment, to more aggressive forms that should be treated. Men who have mutations in the BRCA1 or BRCA2 genes are at a higher risk for developing prostate cancer than men without these mutations. These mutations may also increase the risk of being diagnosted with an aggressive form of prostate cancer. Recommendations are to test for mutations in these genes in patients with metastatic disease to determine treatment choice, and for identifying at-risk relatives who may benefit from increased cancer surveillance/ or risk-reducing surgery.

Method: Next-Generation Sequencing (NGS)

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Paraffin-embedded material (FFPE)/Cytology fluids
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Gene (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PALB2, PMS2) See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227